Alireza Zangeneh, Farid Najafi, Ardeshir Khosravi, Arash Ziapour, Homa Molavi, Zahra Moradi, Saeedeh Bakhshi, Fatemeh Khosravi Shadmani, Behzad Karami-Matin, Moslem Soofi
Epidemiological Patterns and Spatiotemporal Analysis of Cardiovascular Disease Mortality in Iran: Development of Public Health Strategies and Policies
Current problems in cardiology
cytomegalovirus cmv infection following allogeneic hematopoietic cell transplantation considerable morbidity mortality foscarnet treatment option requires renal dose adjustment serum creatinine scrbased estimated glomerular filtration rate egfr equations used estimate renal function patients receiving foscarnet cystatin c cysc shown possible alternative data examining cyscbased egfr population sparse primary objective evaluate outcomes patients treated foscarnet dosed utilizing cyscbased egfr versus scrbased egfr analyzed patients transplantation cellular therapies service memorial sloan kettering kids january 2011 september 2021 received allogeneic hematopoietic cell transplantation 14 days foscarnet cmv infection patients cyscbased egfr compared historical cohort patients scrbased egfr outcomes included time cmv clearance death change anticmv therapy cumulative incidence curves causespecific hazards model used analysis 61 analyzed patients differences found cohorts cumulative incidence change anticmv therapy p 017 death p 069 adjustment multiple confounders patients scr cohort seemed higher chance cmv clearance compared cysc cohort difference statistically significant hazard ratio 242 p 0089 patients received corticosteroids appeared lower incidence cmv clearance p 0056 find differences outcomes dosing foscarnet using cysc versus scr treatment cmv infection